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Ki-67, p53, and BCL-2 are now emerging as markers for classifying breast cancer, guiding 
therapy and predicting treatment responses and prognosis. Restricted data currently exist on 
these molecular markers in Tanzania; hence, we assessed the expressions of Ki-67, p53, and 
BCL-2 and associated them with clinical histopathological features in breast cancer patients 
attending Muhimbili referral hospital in Tanzania. This retrospective cross-sectional hospital-
based study was carried out between 2016 and 2017.  For this research, only women were 
chosen with proven breast cancer, complete clinical history and accessible paraffin block 
samples. Tissue samples were immunohistochemically stained for Ki-67, p53, and BCL-2, 
with respect to their specific Monoclonal Mouse Anti-Human. The relationship between Ki-
67, p53 and BCL-2 expressions and clinical histopathological features was determined using 
a multinomial linear regression model. Only 76 cases met the inclusion criteria for this study, 
with a mean age of 51.32 ±14.28 years. Of these, 86.4% were stage III and IV, whereas 
83.5% cases had grade 2 and grade 3. Upon immunostaining, 85.5% and 57.9% were Ki-67 
and BCL-2 positive, respectively. Log-linear analysis showed no statistically significant 
association among biomarkers expression and CH features. However, multinomial linear 
regression showed higher possibility for association between Ki-67+, p53- and BCL-2+ with 
age, grade, stage and tumor (T) stage. BCL-2 was positively correlated with Ki-67 expression 
contrary to p53, which was negatively correlated with BCL-2. Conclusively, there is 
evidence of correlation between the studied markers with CH features making these markers 
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As a heterogeneous disease with various features, previous studies have shown that breast 
cancer (BC) formation results from mutations and atypical changes in the genes responsible 
for modulating cells growth and upholding their health (Jagusch, 2010). Prompt detection of 
breast cancer plays clinical prominence, and can be used to make treatment decisions when 
adjuvant therapy is most probable to react with efficacy to clients. Despite the hostile price, 
efficient input, and scarcity of useful information for cancer management, biomarker test has 
shown a promising outcome in determining prognosis, and facilitating treatment planning for 
breast cancer management (Zaha, 2014).  
Ki-67 is a nucleus protein originally identified in 1980s as a proliferative marker, merely 
identified in cellular division (G1, S, G2 and M-phase) (Li, Jiang, Chen & Zheng, 2015). 
Over the years, Ki-67 has been correlated with clinical and histopathological factors for 
prognosis of many cancers, including breast cancer. Furthermore, other biomarkers such as 
p53 and BCL-2 have also attracted attention from researchers. p53 is a tumor suppressor 
gene which normally limits cell development by monitoring quick cells division into new 
cells and rectifying DNA mismatched, but it is also a significant prognostic marker in early 
breast tumor screening. p53 expression has been demonstrated by diverse authors to be part 
of  up to 50% of breast tumor through DNA impairment, oncogene activation, hypoxia, 
oxidase stress, viral infection (Shapochka, Zaletok & Gnidyuk, 2013).  BCL-2 is responsible 
for promoting cell survival, inhibiting the action of pro-apoptotic antigen, and is expressively 
associated with hormone receptor status, because of its expression in ordinary breast 
glandular epithelium and estrogen-upregulated.  
Molecular expression profiles for tumor markers such as Ki-67, p53 and BCL-2, are  
currently emerging as  indicator  for classifying breast cancers, guiding therapy, and 
forecasting treatment responses and prognosis (Sejal & Beiyun, 2011). However, biomarkers 
testing, especially for Ki67, p53 and BCL2 molecular markers are unfortunately not available 
or not routinely performed in many developing countries such as Tanzania, apart from 




To date, Tanzania has not yet carried out a population-based study that could give a true 
picture of the national cancer burden. Moreover, the associations (and their mechanisms) 
between prognostic factors for BC new biomarkers, such as Ki67, p53 and BCL-2 remain 
under examined as diagnostic test in the country. The current study aimed at examining Ki67, 
p53 and BCL-2 expressions as prognostic markers concomitantly associated with clinical and 
histopathological factors in Tanzanian patients with BC using immunohistochemistry 
technique in order determine to potential of these markers being use as tools for evaluating 
treatment response in individualized therapeutic schemes 
1.2 Problem statement 
BC has been and still remains an important chronic disease with major public health 
importance, causing preeminent global mortality and morbidity after cervical cancer. Over 
one million cases are identified with BC in which more 410 000 patients die annually in the 
world (Ghoncheh, Pournamdar & Salehiniya, 2016). Along these lines, Tanzania projected 
an amplified breast cancer cases of 2732 in 2012 to 4961 in 2030 (MoHCDGEC, 2017); 
whereas nearby 80% of these patients are likely to die. However, current status shows an 









Figure 1: Estimated burden of breast cancer from 2012 to 2030 in Tanzania 
(Source: Report from Ministry of Health, Community Development, Gender, Elderly    
and Children  of   Tanzania, March 2018) 
 
Countless investigation linked the high incidence and mortality of disease to restricted 
diagnostic services, deficiency of effective treatment to those patients with BC and lack of 
information on additional bio-markers specially Ki-67, p53 and BCL-2 to guide treatment 
choice and possible prognosis. Moreover, prognosis of BC and treatment outcome has also 
been linked to high expression of prognostic markers such as Ki-67, p53, and BCL-2 (Angel, 
Carmen Del Rio, José, Michel & Álvaro, 2014; Mbonde, Amir, Akslen & Kitinya, 2001; 
Nalwoga, 2010). Unluckily, in many low-resource countries, including Tanzania, the 
assessment of bio-markers is either not available or not regularly used to guide therapeutic 
choice and possible prognosis (Silverstein, Sood & Costas-Chavarri, 2016). Understanding 
histological characteristics of breast cancer and their associated prognostic markers is 
therefore essential for determining prognosis and select suitable systemic therapy for 
patients. This will improve the treatment outcome and prove health of BC patients. 
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1.3 General objective 
To assess BC biomarker expressions (Ki-67, p53 and BCL-2) and their associations with 
clinical histopathological features in designated breast cancer patients at Muhimbili National 
Hospital, Tanzania. 
1.4 Specific objectives 
(i) To define the clinic-histopathological characteristics and expression levels of Ki-67, 
p53 and BCL-2 using Immunohistochemistry in patients with breast cancer.  
(ii) To associate Ki-67, p53 and BCL-2 expression levels with clinical histopathological 
features.   
1.5 Research question 
Does any link exist between Ki-67, p53, and BCL-2 bio-markers and the clinical 
histopathological features of breast cancer (stage, tumor size, type, grade and age) in 
Tanzanian patient breast cancer cohort? 
1.6 Significance of the study 
A better understanding of expression of Ki-67, p53, and BCL-2 associated to clinical 
histopathology feature of BC using sensitive and specific immunohistochemical (IHC) 











Breast cancer is one of the most prevalent cancer in African females and often diagnosed in 
advance phase, largely due to scarcity of timely detection and screening and being fatal 
among 56 per cent of Tanzanian women according to Cancer Care Foundation.  
It is the third most frequent female cancer following cervix cancer. Further, it is the second 
most prevalent source of  death amongst Tanzanian women (MoHCDGEC, 2018) (Fig. 2). 
While BC incidence rates are greater in developed countries than developing countries, 
lethality rates are excessively higher in developing countries (MoHCDGEC, 2017), owing to 
inadequate ability to  implement prevention, early detection and therapeutic programs. The 
lifetime risk of BC among females in Tanzania is 1 in 20 and roughly half of all Tanzanian 







Figure 2: Distribution of cancer in Tanzania 
Source: MoHCDGEC, United Republic of Tanzania (2018) 
Histopathology, therapy reaction, metastatic models and result of breast cancer are 
heterogeneous (Eccles et al., 2013; Kontzoglou et al., 2013; Viale, 2012). Built on such 




2.2 Association between tumor biomarkers and breast cancer 
Tumor markers, also called bio-markers, are biomolecules found at upper/lower than normal 
levels in different samples such as blood, urine, or body tissue of some people with disease or 
cancer. Most of those bio-markers are often implicated in regulation of cell functions, like 
apoptosis, cell proliferation or cell surviving. One example of cancer markers is tumor 
suppressor genes, which may be down-regulated in cancer (Mantovani, Collavin & Del Sal, 
2018). 
Numerous studies have shown implication of Ki-67 as nuclear protein that serves as an 
indicator for cell proliferation, and has also been correlated with clinic histopathology and 
prognosis of many cancers, including BC (Shapochka, Zaletok & Gnidyuk, 2013; Strand et 
al., 2013; Zaha, 2014).  Other bio-markers like p53, BCL-2 have also attracted attention from 
researchers. p53 is a tumor protein (also called TP53) encoded by p53 tumor suppressor gene 
that normally limits cell growth by monitoring quickly dividing cells, restoring inconsistent 
DNA, and regulating apoptosis, but it is also a key prognostic marker in early detection of 
BC (Dumay et al., 2013; Gasco, Shami & Crook, 2002).  BCL-2 is an antiapoptotic cell 
protein encoded by the BCL-2 gene and has an imperative effect for promoting cell survival, 
inhibiting the action of pro-apoptotic antigen. BCL-2 is also associated with hormone 
receptor status, because of its manifestation in normal breast glandular epithelium and 
upregulated by estrogen. In addition, Ki-67, p53 and BCL-2 f are the most significant and 
helpful predictive variables presently accessible for endocrine treatment. 
Therefore, it is necessary to evaluate a feasible connection between the manifestation of 
these biomarkers, clinical pathological condition and the risk of BC in Tanzanian women. 
2.3 Data restriction on breast tumor markers test in Tanzania 
One of BC’s diagnosis constraints encountered in Africa is molecular characterization of 
tumor markers in patients. Several investigations have put forward that African BC is largely 
caused by overexpression of hormone receptors (Silverstein et al., 2016). Pathologists and 
researchers working in low resource countries have been challenged as regards to the 
Standard Operating Procedures (SOPs) for IHC staining, due to many reasons, including 
outperformance of surgery, pre-treatment of tissue samples, poor quality specimens from 
large and necrotic tumors, doubtful quality of fixative materials, lengthy stay in fixative 
chemical (regularly for several weeks), poor laboratory techniques and quality 
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assurance/quality control practices, which often lead to  inapplicability of advanced 
immunohistochemistry techniques (Kabel, 2017). 
In Tanzania, a small number of studies are accessible on IHC performance in molecular 
classification of BC markers like Ki-67, p53 and BCL-2. In total, there are 169 district 
hospital and 30 regional referral hospitals in which four are public referral and zonal 
hospitals; Muhimbili National Hospital (MNH) for the coastal zone, Mbeya Referral Hospital 
(MRH) in the Southern highlands zone, Bugando Medical Centre (BMC) in the lake zone, 
and Kilimanjaro Christian Medical Centre (KCMC) in the Northern zone (MoHCDGEC, 
2017). Unfortunately, not all healthcare activities related to BC care are conducted as 
planned compounded with the limitation of human resources and the supply of important 
health commodities. The four public referral and zonal hospital as well as Aga Khan Hospital 
(AGH) are the most prominent medical centres that offer cancer screening services. 
However, chemotherapy, and palliative therapy are only offered by the Ocean Road Cancer 
Institution (ORCI). Nevertheless, they lack diagnostic facilities such as IHC technique. 
Meanwhile, all cancer patients in the regional and peripheral zones are directed to MNH for 
HR and Her-2 examination or other IHC tests. This institution offers an original assessment 
of BC instances identified in Tanzania where they lack a population-based registries (Burson 
et al., 2010; MoHCDGEC, 2017). 
Burson et al. (2010) performed a two-year survey in Tanzania using medical record 
information from all breast cancer clients entering the Ocean Road Cancer Institute (ORCI) 
between July 2007 and June 2009.  
Their research revealed that the frequency or molecular characteristics of breast cancer in 
Tanzania are little understood (Burson et al., 2010). The MNH provides radio and 
chemotherapy for breast cancer patients in partnership with ORCI. However, this 
collaboration offers extremely specific treatment, but both clinics are overcrowded with 
lengthy waiting times for critical facilities as surgery and pathology assessment 
(MoHCDGEC, 2017), and therefore treatment outcomes are not really sensitive. Thus 
improving healthcare facilities for early diagnostic and cancer management is needed. 
A 2017 study from the MoHCDGEC of Tanzania showed that the fraction of BC patients 
expressing hormone receptors in various medical centre could be substantial and significantly 
affected for therapeutic plans (endocrine therapy). Hence, the current queries are: how other 
prognostic bio-markers such as Ki-67, p53 and BCL-2 are expressed vis-à-vis age, stage and 
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grade in patients with BC in these specialized hospitals?  Is there any correlation between 
expression of these other bio-markers and clinical histopathological features of breast cancer 
cases admitted at MNH?   
2.4 Implication of Biomarkers test on personalized medicine 
Bio-markers are usually split into prognostic, predictive and therapeutic response markers. 
Prognostic biomarkers enable the forecast of an external cancer's natural cycle, thus 
enabling the distinction between benign tumors and aggressive tumors.  
The majority of the biological markers have been found through molecular profiling 
research relying on connection or interrelation between a molecular pattern with the 
diseases behavior and are used to evaluate the likelihood of a person being given a special 
therapy (personalized medicine). 
Most bio-markers have been discovered by molecular profiling studies based on the 
association or correlation with molecular signature and disease behavior, and are used to 
evaluate the probability that a patient will benefit from a particular treatment (personalized 
medicine).  
One of the initial molecular profiling studies  reported by Golub et al. (1999)  demonstrated 
that gene expression patterns could classify tumors, thereby providing new perspectives into 
pathological tumor, such as its stage, grade, clinical history, and therapeutic response (Golub 
et al., 1999). Through scientific progress, immunohistochemistry was revealed to be a 
sensitive and specific technique used to identify biomarkers to gain knowledge on diagnosis 
and treatment outcome predictors (Duraiyan, Govindarajan, Kaliyappan & Palanisamy, 
2012). Overall, these studies have highlighted the condition of Tanzanian (African) women 
with BC most of whom present the disease at progressive phase, as well as the influence of 
tumor markers on the expansion of BC in distinction to the rest of the developed country. 
Most health-related projects in Tanzania have focused on communicable disease such as 
tuberculosis, HIV,  and female and child health ((WHO), 2016), which have reinforced the 
safety scheme and could also be leveraged to enhance breast cancer care.  
In summary, improvements of BC management, including development of management 
guidelines, improvement of pathology amenities, and inclusion of immunohistochemistry 
for biomarkers assessment as a routine cancer management procedure, could have a 
progressive influence on the survival of persons with the disease, and may open further 
10 
 





MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Study area 
The present research was performed at the Muhimbili National Hospital's Central Pathology 
Laboratory in Dar es Salaam, Tanzania. MNH acts both as a Coastal Zone and as domestic 
referral and educational center for universities. It has a 1500-bed ability, supplying 1000 to 
1200 weekly outpatients, and accepting 1000 to 1200 daily inpatients. It is the primary 
clinic with Diagnostic Laboratory Department, consisting of six facilities, as well as the 
Center Pathology Laboratory (CPL), which provides excellent engineering facilities 
(histology, hematology, clinical engineering and immunohistochemistry). 
3.1.2 Patients and sample collection 
This was a retrospective cross-sectional hospital based study in which patients were self-
presented or referred from different hospitals to the department of pathology for general 
surgery. From 775 total patients, 76 out of 391 cases qualified for inclusion criteria for 
samples analyzed for Ki-67, p53 and BCL-2 biomarkers via immunohistochemistry (IHC). In 
addition, the selected patients were considered with primary tumor without neo-adjuvant 
treatment. Patient information was retrieved from data routinely reviewed and documented in 
cancer registry and electronic system. The exclusion criteria involved 384 patients who were 
either male patients with breast cancer, patients with a benign condition, patients with 
secondary breast cancer, missing block tissues and/or those lacking clinic-histopathological 















Figure 3: Distribution of patients and biomarkers categories across different pathological 
characteristics 
3.1.3 IHC reagents 
A microscope frosted slides, Dako kit with Monoclonal Mouse antibody of Ki-67 (Dako 
Monoclonal Mouse Anti-Human, MIB-1 ready to use), p53 (Dako Monoclonal Mouse Anti-
Human, DO-7 ready to use) and BCL-2 (Dako Monoclonal Mouse Anti-Human,124), 
Target Retrieval Solution High pH (50x), Peroxidase-Blocking Reagent (ready-to-use), 
HRP (ready-to-use), DAB + Chromogen, Substrate Buffer as well as Wash Buffer (20x) 
were all provided by Labulax Supplies Limited (Nairobi, Kenya).  Additional materials such 
as xylene and alcohol (100% - 95%) and other operative machine was providing at MNH. 
3.2 Methods 
3.2.1 Study design 
This was a retrospective cross-sectional hospital based study which reviewed Hematoxylin 
and Eosin (H & E) slides, breast cancer registries, retrieved blocks from archives and 
conducted laboratory investigation on breast carcinoma tissue. IHC was applied to 

























3.2.2 Samples size estimation 
The sample size was calculated with the formulation: 𝑵 𝐳
𝟐𝐱 𝐩 𝐱 𝟏 𝐩
𝐞𝟐
. Whereas N denotes 
the lowest sample size for tracking down a noteworthy results for an event and a fixed level 
of risk, z: Confidence level (the standard value of the 95% confidence level will be 1.96), p: 
11% (MoHCDGEC, 2018) estimated proportion with the disease and e: Margin of error 
(generally set at 5%) (Arif, Ayman, Khalid & Humma, 2014). Therefore, 150 samples were 
projected to be analyzed at MNH. However, only 76 samples met inclusion criteria, 
including having all the necessary clinical histopathological information, and were analyzed 
in this study. 
3.2.3 Immunohistochemistry (IHC) assay 
IHC for Ki67 (Dako Monoclonal Mouse Anti-Human, MIB-1 ready to use), p53 protein 
(Dako Monoclonal Mouse Anti-Human, DO-7 ready to use), BCL-2 oncoprotein (Dako 
Monoclonal Mouse Anti-Human, 124), Target Retrieval Solution High pH (50x), Peroxidase-
Blocking Reagent (ready-to-use), HRP (ready-to-use), DAB+Chromogen, Substrate Buffer 
as well as Wash Buffer (20x) were performed on each of 76 tissues section slides manually. 
Tissue block for staining process were obtained following the protocol below: 
(i) Preanalytic method: characterized by a fixative sample removed from breast cancer 
patient in a complex series of chemical solution (10% formal saline for 24 hours) to 
prevent the basic structure from autolysis and tissue pigmentation in a way that 
microanatomy and molecular constituents and biomarker could be localized and 
determined.  
a) Grossing process: basically consisted of specimen description (necked eyes), its 
condition, cut section, selection of proper tissue for microscopic analysis and 
embedding tissue block in a micro-cassette. Different parameters such as the color 
specimen, skin and its extend, shape and size of tumor, margin, lymph nodewere 
assessed for good prognostic under microscope. 
b) Tissue processing: was done through dehydration of (70% to 100%) alcohol for 
water extraction, clearing tissue with xylene then embedding the tissue with molten 
paraffin wax to increase optical differentiation, hardness of the tissue and help for 
easy section and IHC staining using Sakura Vacuum Infiltration Tissue Process 
(VIP6) machine. Thus slide preparation followed through section of paraffin block 
which was positioned on a microtome for a regular paraffin cut section of 3 μm. 
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Paraffin slices were left in floatation water bath at 45°C, to eliminate wrinkles and 
distortions of tissue followed by bonding into a microscopic frosted slides and then 
under placed in a hot plate at 60°C for 24 hours, for getting rid of the wax before 
undertaken analytical phase.   
(ii) Analytical method: Was centered on moisture chamber preparation, application of 10 
minutes absolute xylene on the slides for tissue deparaffinization, 10 dips of tissue 
hydration with 100-95% alcohol and washing slide under water for almost 5 minutes. 
IHC staining process was characterized by application of:  
a) Diluted Target Retrieval Solution (50x) low pH under pressure cooker for 13 minutes, 
followed by Wash Buffer’s slide (20x) for 5 minutes   
b) Peroxidase-Blocking Reagent to the section for 15 minutes, followed by washing 
slide with Wash Buffer (20x) for 5 minutes   
c) Ki-67 (Dako Monoclonal Mouse Anti-Human, MIB-1 ready to use), p53 protein 
(Dako Monoclonal Mouse Anti-Human, DO-7 ready to use), BCL-2 oncoprotein 
(Dako Monoclonal Mouse Anti-Human, 124) as primary antibody for 30 minutes. 
Wash the slide through Wash Buffer (20x) for 5 minutes   
d) HRP (Dextran couple with peroxidase molecules and goat secondary antibody) for 30 
minutes 
e) Washing 3 times the slide with Wash Buffer (20x).  
f) Diluted DAB (diaminobenzidine) + Chromogen reagent (1 drop of chromogen 
reagent to 1 ml of DAB) were applied for 10 minutes on the slides, followed by water 
wash slide.  
Therefore, the slides were counterstained with hematoxylin for 17 dips, followed by 
washing slides with water for 5 minutes and dehydration in 95% to absolute ethanol, then 
by cleaned with xylene and mounting through tissue tek-coverslip machine. Moreover, 
false positive was eluded by a case control test. 
(iii) Post-analytic method: consisted of slide analysis, control performance evaluation, 
output description interpretation and outcome reports 
3.2.4 Histopathology classification 
The histopathological classification of breast cancer was defined in accordance with the 
worldwide TNM (Tumor, Node, and Metastases) classification of divers' cancer by WHO 
2003 (Eble, Tavassoli & Devilee, 2003). However, tumor grade was performed under the 
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Nottingham grading system.  The sub-score of 1 to 3 was consigned on each of the 
following features: the quantity of tubules formation, nuclear pleomorphism, and mitotic 
index. Thus, grade III of cancer was given to any patients with a Nottingham score of 8 or 9. 
Grade II referred to Nottingham scores of 6 and 7, although grade I referred to Nottingham 
scores of 3, 4, and 5. 
3.2.5 Staining assessment 
The cutoff point for IHC staining of Ki-67, p53, and BCL-2 varies from literature and studies 
(Eom, Kim, Lee, Song & Chae, 2016; Inwald et al., 2013; Kim et al., 2015a; Kim et al., 
2015b). Thus microscopic evaluation of the slide sections in this study was designed 
following the common assessment from Eom et al. (2016), Inwald et al. (2013), Kim et al. 
(2015a) and  Kim et al. (2015b) through cell counting by recording cells proliferation, as 
well as the number and intensity of positively stained cells for Ki-67, p53, and BCL-2. 
Positive slides were considered from 10 to more than 14% of the cells stained, with a score 
assessment of 2+ (moderate intensity/moderate proliferation) and 3+ (high intensity/high 
proliferation). In contrast, negative results were observed from the section slides in which 
less than 10-14% of cells were stained, following a score of 0-1+ (absence of cells staining or 
low intensity/low proliferation). The IHC evaluation for each studied biomarker was thus 












Table 1: Microscopic evaluation of IHC staining 
Microscopic evaluation and 
IHC staining assessment 
Low biomarkers expression 
(negative) 
High biomarkers expression 
(positive) 
Ki-67 <14% of Ki67 cells stained >14% of Ki67 cells stained 
p53  <10% of p53 cells stained  >10% of p53 cells stained 
BCL-2 <10% of BCL2 cells stained >10% of BCL2 cells stained 
IHC assessment 
The high intensity of cells 
staining with low proliferation. 
Low intensity of cells staining 
with high proliferation. An 
absence of cells staining. 
High to moderate intensity of 
cells staining with high to 
moderate cells proliferation. 
 
3.2.6 Data handling and statistical analysis 
Laboratory investigation, histopathological reports, as well as clinical data were entered into 
structured check-list and Excel spreadsheet software, following a systematic 
histopathological numbering. Data analysis was performed using SPSS version 23. 
Likewise, the association of clinic-histopathological factors with prognostic biomarkers and 
correlation were calculated using correlation test and Multinomial Linear Regression test. 





RESULTS AND DISCUSSION 
4.1 Results 
Objective 1: To define the clinic-histopathological characteristics and expression levels of 
Ki-67, p53 and BCL-2 using Immunohistochemistry in patients with breast 
cancer. 
4.1.1 Patient investigation 
Retrieval of breast cancer blocks for patients with confirmed breast carcinoma, clinic 
histopathological information and good morphology were selected for analysis between 
December, 2016 and December, 2017 at Muhimbili Hospital. Out of 775 cases recorded as 
admitted or out-patients, 391 (49.4%) Haematoxylin and Eosin (H & E) cases were 
malignant but only 76 (9.6%) cases (Fig. 4) had good morphology (spatial arrangement of the 
cells, morphometric characteristics of the nuclei, tubules formation, and number of cancer 
dividing cells) and complete information met the inclusion criteria. Thus stained for Ki67, 
p53 and BCL-2 biomarkers using immunohistochemistry (IHC) technique. This sample size 













Figure 4: Monograph. a and b: Nuclear positively stained (brown color) for Ki-67 at 10x 
and 40x hpf respectively; c and d: Nuclear negatively stained for Ki-67 at 10x and 
40x hpf respectively; e and f: Nuclear positively stained (brown color) for p53 at 
10x and 40x hpf respectively; g and h: Nuclear negatively stained for p53 at 10x 
and 40x hpf respectively; i and j: Nuclear membrane positively stained (brown 
color) for BCL-2 at 10x and 40x hpf respectively: k and l: nuclear membrane 
negatively stained for BCL-2 at 10x and 40x hpf  respectively; m and n: H&E 
staining for infiltrating ductal carcinoma (IDC) at 10x and 40x hpf* respectively. 
*hpf: High-power field.  
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4.1.2 Clinic-histopathological and biomarkers outcomes in selected patients 
Diagnosis age ranged between 23 to 92 years old with a mean of 51.32 ±14.28 years. Out of 
76 patients classified with breast carcinoma, 74/76 samples were pathologically staged, in 
which 3 (4.1%) and 7 (9.5%) had stage I and II at the initial period of diagnosis in contrast to 
36 (48.6%) and 28 (37.8%) presented at late stage in respect to stage III and IV, with a tumor 
thickness >2cm (T3 and T4) and having more than 3 lymph node (N2 and N3) involved with 
tumor. However, 36 (49.3%) among them had mostly intermediate grade (grade 2), followed 
by 25 (34.2%) of high grade (grade 3) breast carcinoma (Table 2). 
Furthermore, laboratory investigation revealed that most of the patients with invasive breast 
carcinoma (IBC) strongly expressed Ki-67 (Ki-67+) and BCL-2 (BCL-2+), with proportions 
of 65 (85.5%) and 44 (57.9%) respectively. In contrast, high numbers of cases 46 (60.5% of 
patients) expressed negative response to p53 staining (Table 3). Notably, positive biomarkers 
expression was mostly expressed by premenopausal patients (<50 years old) (Fig. 5). There 
was no substantial amount of missing values during the post-analytical phases contrary to the 














Table 2: Patients and clinic-histopathological characteristics 
Characteristic  All(n=76) 
Age (years)* 51.32±14.28 
T stages   
  T1 
  T2 
  T3 





Nodule status   
  N0 13 (17.6%) 
  N1 10 (13.5%) 
  N2 30 (40.5%) 
  N3 15 (20.3%) 
  Nx 6 (7.4%) 
Cancer Grade   
  Grade 1 12 (16.4%) 
  Grade 2 36 (49.3%) 
  Grade 3 25 (34.2%) 
Stage   
  Stage I 3 (4.1%) 
  Stage II 7 (9.5%) 
  Stage III 36 (48.6%) 
  Stage IV 28 (37.8%) 
 
Table 3: Distribution of study population with biomarkers 




Ki-67 65 (85%) 11 (14.5%) 
76 (100%) 
p53 30 (39.5%) 46 (60.5%) 






Figure 5: Distribution of Ki-67, p53 and BCL-2 among age-groups 
Objective 2: To associate Ki-67, p53 and BCL-2 expression levels with clinical 
histopathological features.   
4.1.3 Relationship between clinic-histopathological characteristics and biomarkers 
expression 
The current findings showed that Ki-67 were highly expressed in stage III and/or IV and 
grade 2 and/or grade 3 of breast carcinoma (Fig. 6). This is similar with high expression of 

















Figure 6: Association between Ki-67 and clinical and histopathological grades 
 
 
Figure 7: Association between BCL-2 and clinical and histopathological grades 
 
Multinomial logistic regression analysis investigating the relationship between biomarkers 
and clinico-histopathological characteristics showed that Ki-67, p53 and BCL-2 level 
(p>0.05) were not statistically significantly associated with age, cancer stage, cancer grade, T 













































































outcome (Table 3) when stratified into low and high levels.  The odds ratios for associating 
high Ki-67 expression (as compared to low Ki-67 expression) with cancer grade and tumor 
stage were; OR 1.254; 95 % CI 0.586–2.683 and OR 1.374; 95 % CI 0.705–2.677 
respectively. On the other hand, the odds ratios for associating high BCL-2 exposure (as 
compared to low BCL-2 expression) with cancer grade and tumor stage were; OR 1.170; 95 
% CI 0.512–2.676 and OR 1.533; 95 % CI 0.746–3.149 respectively.  Furthermore, with 
regards to high p53 expression, the odds ratios for associating it with tumor stage were; OR 
1.967; 95 % CI 0.834–4.627 while with low p53 expression, the odds ratios for associating it 
with cancer grade were; OR 1.236; 95 % CI 0.550–2.779.  While these odds ratios do contain 
a null value of 1, which could be because of our smaller sample size (limited by data and 
inclusion criteria), we still think that these results do indicate a potential promise for these 
biomarkers to be confirmed in high-powered studies, as tools for evaluating treatment 
response in individualized therapeutic schemes (Table 4). 
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Table 4: Association of clinic-histopathological factors with Ki-67, p53 and BCL-2 
biomarkers 
Low BCL-2a B 
Std. 









High Ki-67 Age -0.008 0.017 0.2356 0.627 0.991* 0.958 1.025 
Cancer stage -0.344 0.527 0.4279 0.512 0.708 0.252 1.990 
Cancer grade 0.226 0.388 0.3406 0.559 1.254* 0.586 2.683 
T stage 0.318 0.340 0.8763 0.349 1.374* 0.705 2.677 
Nodule status -0.089 0.233 0.1463 0.702 0.914 0.579 1.444 
Histologic subtype -0.224 0.241 0.8666 0.351 0.798 0.497 1.282 
Low Ki-67 Age 0.048 0.030 2.5518 0.110 1.049 0.989 1.114 
Cancer stage -0.275 0.853 0.1042 0.7467 0.759 0.142 4.041 
Cancer grade -0.854 0.740 1.3330 0.248 0.425 0.099 1.815 
T stage -0.113 0.536 0.0444 0.833 0.893 0.312 2.554 
Nodule status 0.167 0.404 0.1715 0.678 1.182* 0.535 2.609 
Histologic subtype -0.025 0.371 0.0048 0.944 0.974 0.470 2.020 
High p53 Age 0.009 0.019 0.2358 0.627 1.009 0.970 1.050 
Cancer stage -0.079 0.626 0.0161 0.898 0.923 0.270 3.154 
Cancer grade 0.002 0.484 1.8117E-05 0.996 1.002 0.387 2.588 
T stage 0.675 0.436 2.3904 0.122 1.965* 0.834 4.627 
Nodule status 0.011 0.271 0.0018 0.965 1.011 0.594 1.720 
Histologic subtype -0.730 0.694 1.1066 0.292 0.481 0.123 1.878 
Low p53 Age -0.006 0.018 0.1446 0.703 0.993 0.958 1.029 
Cancer stage -0.495 0.561 0.7800 0.377 0.609 0.202 1.829 
Cancer grade 0.2121 0.413 0.2651 0.606 1.236* 0.550 2.779 
T stage 0.065 0.356 0.03384 0.853 1.067 0.531 2.146 
Nodule status -0.063 0.252 0.0627 0.802 0.938 0.572 1.540 
Histologic subtype -0.145 0.230 0.3980 0.528 0.864 0.550 1.358 
High BCL-2 Age -0.001 0.018 0.0054 0.941 0.998 0.963 1.035 
Cancer stage -0.542 0.559 0.9396 0.332 0.581 0.194 1.740 
Cancer grade 0.157 0.421 0.1394 0.708 1.170* 0.512 2.676 
T stage 0.427 0.367 1.3573 0.243 1.533* 0.746 3.149 
Nodule status -0.071 0.249 0.0821 0.774 0.930 0.570 1.518 
Histologic subtype -0.456 0.326 1.9561 0.161 0.633 0.334 1.200 
aThe reference category 
*OR>1 has causative effect on the cancer patients 
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4.1.4 Antagonistic expression among Ki-67, p53 and BCL-2 
Throughout the post-analytical microscopic phase, it was interesting to find that   Ki-67, 
BCL-2 and p53 were antagonistically expressed for any combination of two of them. This 
raised the question whether the high levels expression of p53 influenced the level expression 
of BCL-2 and Ki-67.  Statistically tested, p53 showed significant correlation with BCL-2 
(Pearson’s correlation=-0.238, p-value=0.038) with a Covariance = -0.058. In the same way 
BCL-2 was significantly correlated with Ki-67 expression (Pearson’s Correlation=0.331, p-
value=0.004) with a Covariance=0.058. However, no significant correlation has been 
observed between Ki-67 and p53 (Table 5). 
Table 5: Antagonistic biomarkers expression 






Ki-67 biomarker  Pearson Correlation 1 .103 .331** 
 Sig. (2-tailed)  .377 .004 
 Sum of Squares and 
Cross-products  
9.408 1.342 4.368 
 Covariance .125 .018 .058 
 N 
 
76 76 76 
p53 biomarker Pearson Correlation .103 1 -.238* 
 Sig. (2-tailed) .377  .038 
 Sum of Squares and 
Cross-products  
1.342 18.158 -4.368 
 Covariance .018 .242 -.058 
 N 
 
76 76 76 
BCL-2 biomarker Pearson Correlation .331** -.238* 1 
 Sig. (2-tailed) .004 .038  
 Sum of Squares and 
Cross-products  
4.368 -4.368 18.526 
 Covariance .058 -.058 .247 
 N 
 
76 76 76 
**. Correlation is significant at the 0.01 level (2-tailed). 






Limited molecular bio-markers are currently in clinical use for BC management in Tanzania 
as only ER, PR, and HER-2 are used as HR for guiding hormonal treatment of BC., 
However, Ki67, p53 and BCL2 are not used for BC classification or as prognostic bio-
markers for breast cancer management at Muhimbili National Hospital or OCRI. Previous 
studies have demonstrated an exponential increase in numbers of research on bio-markers, 
and regarding new technique of early diagnostic and predictive factors for breast cancer that 
could enhance accuracy treatment.  
As heterogeneous disease with various biomarkers expression, BC was classified in this 
study as luminal A (ER+, PR+ HER2- and low level of Ki-67), luminal B (ER+, PR+ 
HER2+/- and high level of Ki-67), triple negative and enriched HER2 (Liu et al., 2017). 
Similarly, Dumay et al. (2013) suggested that p53 could be more classified in luminal B 
rather than luminal A (Dumay et al., 2013). Besides this classification, most of the patients 
attending MNH with BC were obviously tested for hormonal receptors, as well as HER-2, 
and they were followed by a general application of endocrine therapy with Tamoxifen at 
Ocean Road Cancer Institute (Mabula et al., 2012; Mwakigonja, Lushina & Mwanga, 2017) 
without any complementary biomarkers investigation, which may lead to drug resistance or 
non-responding treatment. 
The current research was conducted on 76 cases retrieved from December 2016 and 
December, to determine the correlation between clinical and histopathological prognostic 
factors with Ki-67, p53 and BCL-2 bio-markers expression in selected BC’s patients at 
MNH, Tanzania. 
However, current findings showed that 86.8% of patients presented with infiltrating ductal 
carcinoma (IDC), followed by 6.6% of lobular carcinoma (ILB) and others. Nonetheless, 
positive biomarkers expression was mostly expressed by premenopausal patients (<50 years 
old) probably due to a mechanism of upregulation regarding to hormonal receptors 
expression. The mean age of 51.32 and diagnosis age ranged from 23 to 92 years old. This 
representative age-group is generally in unison with related studies (Hwang et al., 2018; 
Inwald et al., 2013; Mbonde et al., 2001). 
Numerous studies have described Ki-67 as key biomarker more significantly associated with 
malignant tissue rather than normal tissue. However, in the recent study, the largest number 
of patients had tumors which were Ki-67+, which corresponded mostly to luminal B 
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subtypes. These tumors usually had an intermediate grade; negative p53 (p53-) status, and 
high levels of BCL-2(BCL-2+) expression. Thus many studies claim Ki-67 as a predictor 
biomarkers for neo-adjuvant response (endocrine therapy) (Dai, Xiang, Li & Bai, 2016).  
Based on the relationship between biomarkers expression and clinic-histopathological 
features, results demonstrated that some findings were not obvious in our study, because of 
non-significant statistical results that are most likely due to the low power of our study. In 
this study, bivariate analyses revealed only marginal statistical significance but multinomial 
analysis did not reveal any significance. As both Ki-67/BCL2 and p53 are implicated in cell 
proliferation and apoptosis, they play an essential role in defining tumor growth and may 
more accurately help to define high-risk patients. Hence, patients with high Ki-67, low p53 
and high BCL-2 are more likely to be at high risk of having poor prognosis compared to 
patients with low BCL2 in this study, which needs to be confirmed in bigger studies as 
suggested in this study. 
Comparing this study with Awadelkarim et al. (2012), Shapochka et al. (2013) and Angel et 
al. (2014), our findings herein swerve from these authors. While they found a statistically 
significant relationship between biomarker expression and clinical histopathological features, 
our study found no such statistically significant association, most likely due to limited sample 
size with low power. Following a research study by Angel et al. (2014), 251 cases were 
investigated to establish the affiliation amongst tumor size, lymph node status and 
immunohistochemical expression of Ki-67, p53, and BCL-2 in patients with BC. Their 
research demonstrated a significant association between tumor size with advanced 
histological grade, high cell proliferation (Ki-67 expression) and p53. However, with regards 
to age, their study showed significant association of tumor size among women over 70 years 
old, which is contrary to our findings, where no statistically significant association was 
observed across the age groups with biomarkers. Shapochka et al. (2013) as well reported the 
association between Ki-67 with tumor grade but their conclusion regarding the link between 
p53 and tumor grade was not observed in this current study. Further,  Filip et al. (2008) 
revealed no significant relationship among BCL-2 positivity with tumor grade and primary 
tumors, which concurs with our findings herein (Filip et al., 2008). 
During the post-analytical microscopic phase, it was interested in this current study to find 
that   Ki-67, BCL-2, and p53 were antagonistically expressed for any combination of two of 
them. This begged the question whether the high expression levels of p53 influenced the 
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expression levels of BCL-2 and Ki-67, and vice versa.  When statistically tested, p53 showed 
significant negative correlation with BCL-2. In the same way, BCL-2 significantly correlated 
with Ki-67 expression. However, no significant correlation was observed between Ki-67 and 
p53. p53 is a tumor suppressor protein that is encoded by TP53 tumor suppressor gene, 
which is a transcription factor that regulates genes involved in cellular processes when 
activated by cellular stress responses, which include cell cycle and apoptosis. So p53 is pro 
apoptotic during cellular stress. Mutated p53 is overexpressed in several tumors, including 
breast cancer, where it is associated with higher tumor differentiation, adverse estrogen and 
progesterone receptors, or HER2 status. BCL-2 protein, on the other hand, is encoded by the 
BCL-2 gene and plays an anti-apoptotic role by inhibiting cell death, which results in 
prolonged cell survival. BCL-2 is overexpressed in many cancers and contributes to tumor 
initiation, progression, and resistance to therapy. In many cancers, BCL-2 overexpression 
contribute in the initiation, development, and treatment resistance of tumors. The two 
antagonizing roles of p53 and BCL-2 proteins (Nalwoga, 2010) may therefore explain the 
negative correlation between the two as observed in this current study. 
Antagonistic effect among p53 and BCL-2 expression was reported by Ruth, Ella, Douglas 
and Donald (1997) as well as Subrata, Massimo, Maria, Silvia and Carlo (1994) confirming 
the significant correlation between BCL-2 and p53. They stipulated that the level of BCL-2 
in cells is regulated by the p53 protein on the principle of feedback. Further mechanistic 
studies on the roles of p53 and BCL-2 signaling pathways in BC are thus warranted (Ruth et 
al., 1997; Subrata et al., 1994). With reference to the positive correlation between BCL-2 and 
Ki-67, most of the studies have shown the correlation between BCL-2 and hormonal 
receptors expression in contrast to Ki-67. Shapochka et al. (2013) affirmed in their 
investigation that the level of tumor proliferation was inversely correlated with expression of 
hormonal receptors and BCL-2. Nevertheless, this theory needs further research to support it. 
Besides, this study did not cover the assessment of hormonal receptors (ER and PR) and 
HER2 in association with our new predictive biomarkers, which could give us more 
information on patient survival. 
4.3 Study limitations 
This study did not cover a large number of samples size due to logistic constraints. Numerous 
files were figured neither as archives nor in the system, meaning the system of cancer 
registry and availability of database for cancer patients at the MNH and Tanzania are still 
very weak. This all contributed to our limited sample size. Yet, we still believe that the 
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current results are essential for further research work in understanding the possible diagnostic 




CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
Breast cancer is a heterogeneous disorder owing to molecular and histologic modifications 
with regard to tumor biology, clinical behavior, prognosis, and reactions to therapy. In this 
line, currents study aimed to explore novel biomarkers that could be interesting in 
understanding and management of the disease in Tanzanian women. Uppermost levels of Ki-
67 and BCL-2 were expressed by patients under 50 years’ old which is the most productive 
period of women, contrary to the last research finding conducted locally. The studied 
biomarkers herein found that Ki-67, p53 and BCL-2 were highly associated with some 
reported clinical-histopathological features and poor outcomes. As these biomarkers’ 
expression was linked to diverse subtype, including luminal A and Luminal B, this suggested 
that the patients expressing those biomarkers in this study could be sensitive to an endocrine 
therapy. Conclusively, there is evidence of correlation between the studied markers with CH 
features making these markers potential tools for evaluating treatment response in 
individualized therapeutic schemes. 
5.2 Recommendations 
From the conclusion, the following recommendations were made: 
(i) Based on the hormonal receptors targeting BC treatment in Tanzania, it is suitable 
to increase the variety of research on other markers to individualize Tanzania 
therapy systems promptly  
(ii) In order to positively affect the lives of individual breast cancer patients through 
personalized therapy systems, breast-cancer management in Tanzania should 
discover a manner to improve the pathological facilities, including 
immunohistochemistry for screening biomarkers in a regular cancer management 
process. 
(iii) A study with bigger sample size is thus recommended to validate the findings 
from this study, including studying the mechanisms involved in the observed 
differences among association of markers’ expressions and respectively studied 
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Appendix 1: Check list 
Study area: Muhimbili National Hospital- Tanzania 
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